2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
16
Ovarian Neoplasms
12
Breast Neoplasms
9
Fallopian Tube Neoplasms
6
Carcinoma, Ovarian Epithelial
5
Squamous Cell Carcinoma of Head and Neck
4
Endometrial Neoplasms
4
Triple Negative Breast Neoplasms
3
Neoplasm Metastasis
3
Lung Neoplasms
3
Esophageal Squamous Cell Carcinoma
3
Carcinoma
3
Uterine Neoplasms
2
Uterine Cervical Neoplasms
2
Non Small Cell Lung Carcinoma NSCLC
2
Neoplasms, Unknown Primary
2
Neoplasms
2
NSCLC
2
Melanoma
2
Esophageal Neoplasms
2
Adenocarcinoma
2
Urologic Neoplasms
1
Urogenital Neoplasms
1
Unresectable Stage III NSCLC
1
Triple Negative Metastatic Breast Cancer
1
Thyroid Neoplasms
1
Thrombocytopenia
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcopenia
1
Interventions
Gemcitabine
9
pembrolizumab
7
Cisplatin
5
enfortumab vedotin
4
atezolizumab
4
Trastuzumab
4
Mitomycin
4
Carboplatin
4
Sunitinib
3
Pemetrexed
3
dodecyl maltoside
2
cabozantinib
2
Water
2
Sugammadex
2
Standard of Care
2
Saline Solution
2
Paclitaxel
2
Nivolumab
2
Neostigmine
2
Docetaxel
2
Cetuximab
2
Bevacizumab
2
zidovudine 5'-monophosphate-mannose-albumin conjugate
1
vinflunine
1
valrubicin
1
tucatinib
1
tislelizumab
1
testosterone 17 beta-cypionate
1
temsirolimus
1
relatlimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urologic Neoplasms
×
CP protocol
×
Clear all
NCT06353906
2025-12-08
PRIAM
The Netherlands Cancer Institute
Phase 2
Recruiting
27 enrolled